Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
Ryo AriyasuNoriko YanagitaniKenichi TadokoroToshikazu YamaguchiKen UchiboriSatoru KitazonoNaoya FujitaRyohei KatayamaMakoto NishioPublished in: Cancer chemotherapy and pharmacology (2020)
BIM polymorphism does not affect EGFR-TKI efficacy.